ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2016
The Pandemic H30 Subclone of Escherichia coli Sequence Type 131 Is Associated With Persistent Infections and Adverse Outcomes Independent From Its Multidrug Resistance and Associations With Compromised Hosts.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 47 citations in OpenAlex.
- Escherichia coli ST131 Drives Carbapenem Use for E. coli Bloodstream Infections.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Genomic Markers Distinguishing Shiga Toxin-ProducingPathogens (Basel, Switzerland) · 2025Article
- Predicting sepsis mortality into an era of pandrug-resistant E. coli through modeling.Communications medicine · 2024Article
- Gut residentmedRxiv : the preprint server for health sciences · 2024Article
- Clonal and resistance profiles of fluoroquinolone-resistant uropathogenicFrontiers in microbiology · 2024Article
- Longitudinal molecular analysis of clinical and fecalFrontiers in microbiology · 2024Article
- Escherichia coli ST131 Associated with Increased Mortality in Bloodstream Infections from Urinary Tract Source.Journal of clinical microbiology · 2023Article
- The impact of the ST131 clone on recurrent ESBL-producing E. coli urinary tract infection: a prospective comparative study.Scientific reports · 2022Article
- Bacterial genotypic and patient risk factors for adverse outcomes in Escherichia coli bloodstream infections: a prospective molecular epidemiological study.The Journal of antimicrobial chemotherapy · 2022Article
- Exploiting genomics to mitigate the public health impact of antimicrobial resistance.Genome medicine · 2022Review
- Risk Factors for Extended-Spectrum-β-Lactamase-ProducingAnnals of laboratory medicine · 2021Article
- Bloodstream Infections Caused by Extended-Spectrum Beta-Lactamase-ProducingPathogens (Basel, Switzerland) · 2021Article
- Characterizing the cytotoxic effects and several antimicrobial phytocompounds of Argemone mexicana.PloS one · 2021Article
- Extended-Spectrum-β-Lactamase- and Plasmid AmpC-Producing Escherichia coli Causing Community-Onset Bloodstream Infection: Association of Bacterial Clones and Virulence Genes with Septic Shock, Source of Infection, and Recurrence.Antimicrobial agents and chemotherapy · 2020Article
- Large Fecal Reservoir of Escherichia coli Sequence Type 131-H30 Subclone Strains That Are Shared Within Households and Resemble Clinical ST131-H30 Isolates.The Journal of infectious diseases · 2020Article
- Whole-genome analysis of extraintestinalMicrobial genomics · 2020Article
- The Uropathogenic Escherichia coli Subclone Sequence Type 131-H30 Is Responsible for Most Antibiotic Prescription Errors at an Urgent Care Clinic.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Article
- The burden of antimicrobial resistance among urinary tract isolates of Escherichia coli in the United States in 2017.PloS one · 2019Article
- Prevalence and risk factors for colonization by extended-spectrum β-lactamase-producing or ST 131Infection and drug resistance · 2019Article
- Clinical Impact of Sequence Type 131 in Adults with Community-Onset MonomicrobialJournal of clinical medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundThe H30 subclone within Escherichia coli sequence type 131 (ST131-H30) has emerged rapidly to become the leading antibiotic-resistant E. coli strain. Hypervirulence, multidrug resistance, and opportunism have been proposed as explanations for its epidemic success.
methodsWe assessed 1133 consecutive unique E. coli clinical isolates from 5 medical centers (2010-2011) for H30 genotype, which we compared with epidemiological and clinical data extracted from medical records by blinded reviewers. Using univariable and multivariable logistic regression analysis, we explored associations of H30 with underlying host characteristics, clinical presentations, management, and outcomes, adjusting for host characteristics.
resultsThe H30 (n = 107) isolates were associated with hosts who were older, male, locally and systemically compromised, and healthcare and antibiotic exposed. With multivariable adjustment for host factors, H30 lost its numerous significant univariable associations with initial clinical presentation, but remained strongly associated with clinical persistence (odds ratio [OR], 3.47; 95% confidence interval [CI], 1.89-6.37), microbiological persistence (OR, 4.46; 95% CI, 2.38-8.38), subsequent hospital admission (OR, 2.68; 95% CI, 1.35-5.33), and subsequent new infection (OR, 1.73; 95% CI, 1.01-3.00). These host-adjusted associations remained strong even with added adjustment for resistance to the initially prescribed antibiotics, and the adverse outcome associations (subsequent hospital admission, new infection) were independent of clinical and microbiological persistence.
conclusionsIn addition to targeting compromised hosts and resisting multiple antibiotics, H30 isolates may have an intrinsic ability to cause highly persistent infections and later adverse outcomes. The basis for these host- and resistance-independent associations is unclear, but they should be considered when managing patients with H30 infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.